title: Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies.
abstract: We present here a systematic analysis of lymphoma and MM patients recruited into 2 clinical trials or treated with radretumab according to compassionate use, describing the biodistribution, dosimetry, safety, and clinical activity of radretumab.
  
  
  METHODS
  Uptake in lymphoma lesions, safety, and clinical activity of radretumab radioimmunotherapy (R-RIT) were evaluated in 18 relapsed lymphoma or multiple myeloma patients.
  
  
  RESULTS
  In 14 of 18 patients, selective tumor uptake was found; 11 of 15 lymphoma patients, including 9 of 11 with Hodgkin lymphoma (HL), were eligible for R-RIT (a priori criteria-based target-to-bone marrow ratio > 10:1 for EudraCT no. 2005-000545 or > 4:1 for EudraCT no. 2007-007241-12 at dosimetric imaging). Two HL and 1 diffuse large B cell lymphoma patient achieved complete response; 1 HL patient had partial response. Both multiple myeloma patients receiving R-RIT experienced stabilization of disease. Therefore, the overall objective response rate was 40%. Uncomplicated grade 3-4 thrombocytopenia or leukocytopenia was observed in 5 R-RIT patients, lasting 4-129 d.
  
  
  CONCLUSIONS
  R-RIT showed a favorable benefit and risk profile in advanced relapsed lymphoma patients and induced complete response in 2 heavily pretreated, relapsed HL patients and in 1 diffuse large B cell lymphoma patient. These results warrant further exploration of R-RIT in larger phase II clinical trials.
authors.affiliation: Regional Center of Nuclear Medicine, University of Pisa Medical School, Pisa, Italy. p.erba@med.unipi.it
authors.forename: Paola A
authors.initials: PA
authors.lastname: Erba
authors.forename: Martina
authors.initials: M
authors.lastname: Sollini
authors.forename: Enrico
authors.initials: E
authors.lastname: Orciuolo
authors.forename: Claudio
authors.initials: C
authors.lastname: Traino
authors.forename: Mario
authors.initials: M
authors.lastname: Petrini
authors.forename: Giovanni
authors.initials: G
authors.lastname: Paganelli
authors.forename: Emilio
authors.initials: E
authors.lastname: Bombardieri
authors.forename: Chiara
authors.initials: C
authors.lastname: Grana
authors.forename: Leonardo
authors.initials: L
authors.lastname: Giovannoni
authors.forename: Dario
authors.initials: D
authors.lastname: Neri
authors.forename: Hans D
authors.initials: HD
authors.lastname: Menssen
authors.forename: Giuliano
authors.initials: G
authors.lastname: Mariani
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D057176:Compassionate Use Trials; D005260:Female; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000009:adverse effects; D012008:Recurrence
chemical_list: D005353:Fibronectins; D007457:Iodine Radioisotopes